Dauricine regulates prostate cancer progression by inhibiting PI3K/AKT-dependent M2 polarization of macrophages

Copyright © 2023. Published by Elsevier Inc..

M2 type tumor-associated macrophages, an essential component of the tumor microenvironment (TME), have been proved to contribute to tumor metastasis. Dauricine (Dau) has recently received widespread attention due to its multiple targets and low price. However, the effect of Dau on macrophage polarization of TME remains unclear. In this study, we investigated the effect of Dau on prostate cancer (PCa) metastasis and specifically its correlation to macrophage polarization. Our results showed that Dau efficiently suppressed M2 polarization of macrophages induced by interleukin (IL) -4 and IL-13. Mechanistically, Dau inhibited the activity of PI3K/AKT signaling pathway, which subsequently suppressed macrophage differentiation to M2 type. Importantly, our study indicated that Dau decreased the release of chitinase 3-like protein 1 (CHI3L1) from M2 macrophages, which ultimately inhibited the M2 macrophage-mediated progression of PCa cells in vitro and in vivo. Taken together, our data demonstrated that Dau suppressed M2 polarization of macrophages via downregulation of the PI3K/AKT signaling pathway, in turn, preventing proliferation, epithelial-mesenchymal transition, migration, and invasion of PCa cells. Thus, this study reveals a previously unrecognized function of Dau in inhibition of PCa progression via intervention in M2 polarization of macrophages.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:217

Enthalten in:

Biochemical pharmacology - 217(2023) vom: 30. Nov., Seite 115838

Sprache:

Englisch

Beteiligte Personen:

Li, Mengxuan [VerfasserIn]
Che, Nan [VerfasserIn]
Liu, Xingzhe [VerfasserIn]
Xuan, Yanhua [VerfasserIn]
Jin, Yu [VerfasserIn]

Links:

Volltext

Themen:

8QTO90G5W5
Dauricine
EC 2.7.1.-
EC 2.7.11.1
Journal Article
M2 polarization
Migration
Phosphatidylinositol 3-Kinases
Prostate cancer
Proto-Oncogene Proteins c-akt
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 06.11.2023

Date Revised 06.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.bcp.2023.115838

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM36274324X